Reagents, Reference Materials & Laboratory Chemicals


iPSC protocol advances research into male infertility treatments


Amsbio highlights recent progress by the Sasaki Lab at the University of Pennsylvania’s School of Veterinary Medicine in developing a novel protocol that uses induced pluripotent stem cells (iPSCs) to create reconstituted human testes.


Since their pioneering 2020 study, Dr Kotaro Sasaki’s team has made significant strides in generating human testis-like tissue from iPSCs. Their latest breakthrough, detailed in a 2025 blog update, introduces a refined method for producing xenogeneic reconstituted testes (xrTestes) capable of supporting human spermatogonial development in vitro.


This advancement reinforces the Sasaki Lab’s system as a powerful and scalable model to study early human spermatogenesis, providing a valuable platform for reproductive biology research. These developments could open new pathways for investigating and developing treatments for male infertility.


Supporting these efforts, Amsbio supplies a comprehensive range of reagents designed for stem cell culture, differentiation, and 3D tissue modelling.


The Sasaki Lab relies on Amsbio’s StemFit® feeder-free, chemically defined media to maintain their iPSC cultures. For coating culture plates, they use recombinant laminin E8 fragments delivered via iMatrix-511 silk from Amsbio. The lab also preserves cells with CELLBANKER 1, a trusted cryopreservation solution for sensitive cell lines. Additionally, CELLOTION™ cell wash and recovery solution is employed for collecting FACS-sorted cells before single-cell RNA sequencing.


To explore the Sasaki Lab’s latest advances in iPSC-derived human testes research, read the full 2025 blog update from Amsbio: ilmt.co/PL/9MOl More information online: ilmt.co/PL/kkbx


65488pr@reply-direct.com Validated reagent kits for HCP quantifi cation


Gyros Protein Technologies AB, a leader in automated nanolitre-scale immunoassays and advanced peptide synthesis, has announced the release of two new host cell protein (HCP) quantification kits: the Gyrolab® HEK293 HCP Type SN Kit Reagents and Gyrolab HEK293 HCP Type CL Kit Reagents. These kits, developed in collaboration with BioGenes GmbH, are designed to support streamlined and sensitive HCP detection in biotherapeutics derived from HEK293 cell lines.


HCP removal is essential in biologics development to ensure product purity and safety. These impurities can provoke immune responses ranging from mild allergic reactions to severe complications, making their removal a regulatory and clinical priority. The new Gyrolab kits offer a robust solution for detecting HCPs with improved sensitivity and broad antigen coverage.


The kits are fully validated and ready to use on Gyros Protein Technologies’ automated Gyrolab immunoassay platform. By offering pre-optimised, plug-and- play reagent kits, the company enables faster, more reproducible HCP analysis with reduced sample and reagent consumption - improving both throughput and efficiency in analytical workflows.


While Gyrolab users have previously been able to use BioGenes’ antibodies with custom methods, the launch of these standardised kits simplifies implementation and enhances performance. The kits benefit from BioGenes’ proprietary 360-HCP antibody development strategy, which uses multiple host species, refined antigen preparation, and optimised purification to ensure exceptional antigen coverage and antibody quality.


More information online: ilmt.co/PL/Kwzw 64848pr@reply-direct.com


Circular Dichroism beyond single-point checks: First accredited ISO 17025 CRMs deliver spectrum-wide confi dence


Circular Dichroism (CD) spectroscopy is central to structural biology and chiral analysis. However, in 2025, many laboratories still rely on camphor-10- sulfonic acid (CSA) or ammonium camphorsulfonate (ACS) for instrument verification. These traditional methods require fresh preparation, are prone to hygroscopic error, and only validate a single peak near 290 nm. The result: The visible range goes untested, and compliance is left exposed.


Starna leads the industry with its Certified Reference Materials (CRMs) for CD. Each set contains permanently flame-sealed quartz cells – Blank, R,R, and S,S enantiomers – spanning both UV and visible regions (190–700 nm and 400–700 nm). Ready-to-use, these references eliminate weighing and waiting, removing preparation variability and ensuring reproducibility across instruments and locations.


Certification extends beyond static tables. Every set features a continuous ∆ε(λ) model and U95 uncertainty envelopes, so users can verify performance at any wavelength with confidence. For those who prefer a rapid check, certificates highlight key maxima and minima: anchor points at 210, 237, 274, and 545 nm for UV, and 446, 479, 545, and 605 nm for VIS. Spot-checking instrument performance becomes straightforward, with no need for complex calculations. Certificates are valid for two years, offering lasting assurance between renewals.


As the first and only producer with an accredited (UKAS) scope for CD CRMs, Starna combines ISO 17034 production and ISO/IEC 17025 calibration for unmatched traceability and compliance. This achievement ensures every set is certified with globally recognised traceability for audit-ready documentation and spectrum-wide reliability.


For regulated environments, the advantages are clear: objective acceptance criteria, reduced operational risk, and data integrity you can defend. Say goodbye to stresses that result from last-minute scrambling to prepare unstable CSA solutions, or worrying about gaps in instrument calibration. With Starna UKAS-accredited CD spectroscopy standards, you can demonstrate compliance and reproducibility across the full spectrum.


Ready to move beyond single-point checks? Request a certificate sample or technical briefing today to experience how Starna Certified Reference Materials can transform your laboratory’s approach to CD instrument qualification.


More information online: ilmt.co/PL/LwWd 65529pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60